Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATFORM: Maintenance Therapy in Oesophago-gastric Cancer
NCT02678182Phase 2Active, not recruiting
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Feb 2015
- Primary completion
- Apr 2025
- Modality
- Antibody Conjugates, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, durvalumab, rucaparib, ramucirumab in oesophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, gastric adenocarcinoma, sponsored by Royal Marsden NHS Foundation Trust. Started Feb 2015; status: active, not recruiting.
02
Drugs
capecitabinedurvalumabrucaparibramucirumab
03
Conditions
oesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinomagastric adenocarcinoma
Beyond the preview
Go deeper on NCT02678182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02678182.